MF59 is an immunologic adjuvant that uses squalene. It is Novartis' proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory cells.[1][2][3]
MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. MF59 is used as an adjuvant in Canada, Europe and the United States.[4]
MF59 was developed in the 1990s by researchers at Chiron Corporation, a Novartis heritage company, acquired by Novartis in 2006.[5]
^O’Hagan, Derek T; Ott, Gary S; Nest, Gary Van; Rappuoli, Rino; Giudice, Giuseppe Del (2014). "The history of MF59® adjuvant: a phoenix that arose from the ashes". Expert Review of Vaccines. 12 (1): 13–30. doi:10.1586/erv.12.140. PMID 23256736.
^O’Hagan, Derek T; Rappuoli, Rino; De Gregorio, Ennio; Tsai, Theodore; Del Giudice, Giuseppe (2014). "MF59 adjuvant: the best insurance against influenza strain diversity". Expert Review of Vaccines. 10 (4): 447–462. doi:10.1586/erv.11.23. PMID 21506643.
^Trivedi, B. (2006). "Profile of Rino Rappuoli". Proceedings of the National Academy of Sciences. 103 (29): 10831–10833. Bibcode:2006PNAS..10310831T. doi:10.1073/pnas.0604892103. PMC 1544134. PMID 16832044.
^"CDC Flu Vaccine With Adjuvant". Archived from the original on 2017-08-21. Retrieved 2018-10-11.
^MF59 Adjuvant Fact Sheet Archived 2014-03-09 at the Wayback Machine
MF59 is an immunologic adjuvant that uses squalene. It is Novartis' proprietary adjuvant that is added to influenza vaccines to help stimulate the human...
vaccine adjuvants: The Novartis and GlaxoSmithKline adjuvants are called MF59 and AS03, respectively. Squalene is a biochemical precursor to both steroids...
was never released commercially. The oil squalene is used in the adjuvant MF59. Bacterial products: killed bacteria of the species Bordetella pertussis...
candidate used the University of Queensland's molecular clamp technology and the MF59 adjuvant. V451 is a protein subunit vaccine. As part of the vaccine's design...
protein adapted for the subtype C HIV common in sub-Saharan Africa, with the MF59 adjuvant. Those who received the vaccine regimen produced strong immune responses...
detoxified pertussis toxin; the first conjugate vaccines against meningococcus; MF59 adjuvant for influenza; the meningococcus B genome-derived vaccine. During...
manufacturing impurities, or combinations of these factors. 2009 flu pandemic MF59 – another squalene-based adjuvant by Novartis AS04 – another adjuvant by...
safety profile associated with MF59-adjuvanted influenza vaccines and suggests there may be a clinical benefit over non-MF59-containing vaccines". A 2004...
Hora M, Henriksson T, Palla E, et al. (September 2006). "Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene". Clinical...
M, Valente S, Nunzi E, Iorio AM (2015). "Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects...
drops to only 70 million. Trials using adjuvants such as alum, AS03, AS04 or MF59 to try and lower the dose of vaccine are urgently needed. The second problem...
vaccine safety data on adjuvanted pH1N1 vaccines (arenaprix-AS03, Focetria-MF59, and Pandemrix-AS03) from 10 global study sites. Researchers did not detect...
Ndiaye A, Lafond KE, Widdowson MA, Neuzil KM. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines...
liver. The flu vaccine for older adults, Fluad, uses an adjuvant branded MF59, which has squalene (9.75 milligrams), citric acid (0.04 milligrams) and...
Global Information